https://www.businesswire.com/news/home/20260224232925/en/Cartography-Biosciences-Doses-First-Patient-in-Phase-1-Trial-of-CBI-1214-a-Highly-Specific-T-Cell-Engager-for-the-Treatment-of-Colorectal-Cancer

Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer